Table 3.
Results of the cost-effectiveness analysis. Base case (cost and QALYs increase for a hypothetical cohort of 1000 patients)
| Healthcare perspective | Societal perspective | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Combined program | Health advice alone | Difference between the options | Combined program | Health advice alone | Difference between the options | ||||||||
| Mean costs (€) |
Mean QALYs | Mean costs (€) |
Mean QALYs | ΔCost (€) |
Δ QALYs | ICUR €/QALY |
Mean costs (€) |
Mean QALYs | Mean costs (€) |
Mean QALYs | ΔCost (€) |
Δ QALYs | ICUR €/QALY |
| Men | |||||||||||||
| 2,576 | 20.61 | 2,565.80 | 20.59 | 199.93* | 27.07* | 7.40 | 22,014 | 20.61 | 22,160 | 20.59 | − 146,130.25* | 27.07* |
− 5,398 (DOMINANT) |
| Women | |||||||||||||
| 1,888 | 20.98 | 1,855 | 20.96 | 33,333* | 25.10* | 1,327 | 16,829 | 20.98 | 16,912 | 20.96 | − 82,632.81* | 25.12* |
− 3,290 (DOMINANT) |